—utah778—Getty Images On November 9, the U.S. Food and Drug Administration (FDA) approved a new type of medication to reduce the risk of strokes in certain populations.
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke. In a study submitted to the FDA by Bayer, researchers found that the drug, when combined with an antiplatelet therapy such as aspirin, reduced the risk of an additional stroke by 26% in just over a year compared to people who received placebo and the antiplatelet therapy. The drug is approved…
Read the full article at TIME.COM
